1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
about
Regional variations and the effects of age and gender on glutamate concentrations in the human brainClinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Mechanisms of glutamate transportWhat does imaging reveal about the pathology of amyotrophic lateral sclerosis?An integrated strategy for evaluation of metabolic and oxidative defects in neurodegenerative illness using magnetic resonance techniques.The motor cortex and amyotrophic lateral sclerosis.Proton magnetic resonance spectroscopy (1H-MRS) in ALS.25 years of neuroimaging in amyotrophic lateral sclerosis.ALS surrogate markers. MRS.N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease.Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral SclerosisMagnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation.Magnetic resonance spectroscopy of the cervical cord in amyotrophic lateral sclerosis.Peristimulus time histograms (PSTHs)--a marker for upper motor neuron involvement in ALS?Amyotrophic lateral sclerosis: objective upper motor neuron markers.Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS.An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy.Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis.Simultaneous detection of resolved glutamate, glutamine, and gamma-aminobutyric acid at 4 T.Measures and markers in amyotrophic lateral sclerosis.Excitotoxicity and amyotrophic lateral sclerosis.Evaluation of the efficacy of memantine in the treatment of fibromyalgia: study protocol for a doubled-blind randomized controlled trial with six-month follow-up.Interleukin-1beta: a bridge between inflammation and excitotoxicity?Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI.Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study.Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43 model of amyotrophic lateral sclerosis.Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis.The neurobiology of amyotrophic lateral sclerosis.Spinal cord markers in ALS: diagnostic and biomarker considerations.Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis.Endomicroscopy and electromyography of neuromuscular junctions in situProton magnetic resonance spectroscopy in patients with early stages of amyotrophic lateral sclerosis.Study of the features of proton MR spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis.Proton MRS in Kennedy disease: absolute metabolite and macromolecular concentrations.A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results.A prospective pilot study measuring muscle volumetric change in amyotrophic lateral sclerosis.Improved resolution of glutamate, glutamine and γ-aminobutyric acid with optimized point-resolved spectroscopy sequence timings for their simultaneous quantification at 9.4 T.Effects of age and sex on the concentrations of glutamate and glutamine in the human brain.Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis.
P2860
Q24647577-7E942785-DC09-41F5-8FE2-E3434DEFBCACQ26823418-45B605FB-CAD6-4A05-9CA0-5D5E73853A37Q26830761-61141131-5EF4-4F4E-850F-36282B68A371Q27007017-D20851B4-A4E2-43A3-8085-D174BD6E0C55Q30586618-0599BBC9-5DD4-43ED-8FAC-0C02164D44B7Q30641917-0A4F77C9-4875-4DC6-A8BB-2D2603FAEAB2Q30656819-247F5970-EDC9-44DD-A9A9-5AA7A86367DEQ30659482-F28B3F4A-0F39-4771-B165-0068D319C83FQ30974180-E44201DD-2E6B-4E78-870C-4EC6F59EAD8DQ31046921-0746C8B4-6E36-4EC1-9D3F-6EDFCE08EEF9Q33675140-B3B43A02-A4C9-47DF-966D-6F792B953812Q33757934-4C1C0858-C0E5-4215-B95B-697942F108F7Q33766375-40636989-FA9C-4894-928A-E65674F1B0DAQ34314396-F762FBB1-A9DF-4775-9AAE-EE66B69F9421Q34566679-741D71EF-93E9-4BD5-8BD7-D544D465E7AEQ35240090-0CDE34AB-C5AF-4908-8F3B-656A050621F9Q35246605-7FD66104-07D2-4ED4-A969-E127604012F1Q35948547-FA9A41ED-73D5-4E35-B4D8-3FB955E10F8DQ36016388-65E9C07E-94CA-45F2-AD1A-C3FAE65B14CDQ36045308-5F5FC2EA-253A-45A7-997B-D961F9E690EDQ36565667-6EF9F339-2D19-48DF-90B7-FF0C8A4C405FQ36688619-B012CE74-4DFF-4B49-9B35-A195073A0419Q37100241-79DD62AE-2D13-426C-AD74-4BE770585730Q37322633-D9BDFE2E-49F1-45A7-833D-E4138B421E75Q37348418-85742FE2-361B-4B9B-A5E1-35DE0C879692Q37449093-D0C13B8E-7226-4856-8FB0-72D7ED60D088Q37462401-2807D4BC-9CD6-49BE-B55A-D0E3F5D876E2Q37561488-6229C425-C254-43AF-A25C-489F190F6205Q37763285-CF382511-1781-4E0E-BC58-67C83C5106B5Q37983648-445DFE37-6992-4D98-B41B-A4CBB887ACB1Q38983572-1A2CE271-1F42-4F06-BBA7-A1D0652EC9DFQ42593276-8C2740FD-7FE4-4607-B055-2DDCB96A3BEEQ43108890-0B5AAA79-1EC2-43D2-BA65-538639E7EB3FQ43184819-EBAB44DA-AEE6-46FA-BC90-7EB4FFF28C4AQ44120010-D293E5B8-C365-435F-924F-AB3016620059Q44440114-CFEE1F3D-E580-4B3A-AF4F-1F4C530270CDQ44943147-2B00C186-7828-43F3-9FB0-049CF07F14A2Q47985831-F5FF6332-2057-4DC5-853D-312DAE115849Q48092892-32B94A4F-0E5A-4E8E-ABE4-5FA7FC120EA4Q48204378-D77B032B-95D7-4981-8ED6-CD855EBAC756
P2860
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
@en
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
@nl
type
label
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
@en
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
@nl
prefLabel
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
@en
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
@nl
P2093
P356
P1433
P1476
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.
@en
P2093
P356
10.1212/WNL.53.1.71
P407
P577
1999-07-01T00:00:00Z